有効性試験の市場:サービスタイプ(抗菌・防腐剤有効性試験、殺菌剤有効性試験)、用途(医薬品、化粧品・パーソナルケア、医療機器、消費者製品)、地域別 - 2027年までの世界予測Efficacy Testing Market by Service Type (Antimicrobial/Preservative Efficacy Testing, Disinfectant Efficacy Testing), Application (Pharma, Cosmetics & Personal Care, Medical Devices, Consumer Products) and Region - Global Forecast to 2027 効能試験の世界市場は、2022年の3億1500万米ドルから2027年には4億2300万米ドルに達すると予測され、予測期間中のCAGRは6.1%となります。この市場の成長は、主に製薬、バイオ医薬品、化粧品業界において、汚染防... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー効能試験の世界市場は、2022年の3億1500万米ドルから2027年には4億2300万米ドルに達すると予測され、予測期間中のCAGRは6.1%となります。この市場の成長は、主に製薬、バイオ医薬品、化粧品業界において、汚染防止と製品安定性のために表面殺菌剤と防腐剤の使用が増加していること、有効性試験のアウトソーシングを好む傾向が高まっていること、QbDアプローチの採用が増加していることに起因しています。新興市場の高い成長性は、有効性試験市場で活動するプレーヤーに成長機会を提供します。"試験法の種類別では、従来の試験法が抗菌・防腐剤試験市場で最大のシェアを占めている" 従来の試験法は一般的に、長期間にわたる複数の試験点での微生物アッセイを必要とします。試験期間は、最低28日間から12週間以上に及ぶのが一般的です。より長期の一般的なチャレンジプロトコルで採用されているのと同様の標準的な微生物学的技術が関与しているため、アッセイを実施するために特別な設備やトレーニングは必要ありません。実際、この加速二重チャレンジ(ADC)アッセイは、現在、多くの研究所で様々な用途に基本形またはバリエーションで使用されています。 "予測期間中、医薬品製造アプリケーションのセグメントが最も高い成長率を示すだろう" 有効性試験市場は、用途別に、医薬品製造用途、化粧品・パーソナルケア製品用途、消費者製品用途、医療機器用途に区分されます。2021年には、医薬品製造用途が市場最大の製品セグメントとなりました。この市場の成長は、大手製薬会社による研究開発製造の増加、政府の支援、製薬業界の成長、患者の安全性への注目の高まりに起因すると考えられます。 "アジア太平洋地域の市場は、予測期間(2020-2027年)において最も高い成長率を示すと予測されます。" アジア太平洋地域の市場は、予測期間中に最も高いCAGRで成長すると予測されています。これは主に、医療に対する政府支出の増加、老人人口の増加、消費者の健康意識の高まり、慢性疾患の発生率の増加によりこの地域の医薬品の成長の原因となっていること、APAC諸国で製造施設を設立する製薬会社の数が増加していることに起因しています。 「北米:効能試験市場の最大シェア 北米は効能試験市場の最大シェアを占めている。この地域には確立された製薬業界が存在すること、研究開発費が高いこと、大手サービスプロバイダーの存在感が強いこと、この地域の製薬会社や化粧品会社による分析試験(有効性試験を含む)のアウトソーシングが増加していることなどが、市場成長の主要因である。 プライマリーの内訳 本調査には、部品サプライヤーからティア1企業、OEMに至るまで、様々な業界専門家による洞察が含まれています。プライマリーの内訳は以下の通りです。 - 回答者別:供給側80%、需要側20 - 役職別:役員25%、CXO20%、管理職55 - 地域別:北米50%、欧州20%、APAC20%、RoW 10 有効性試験市場で事業を展開する主要企業は、Charles River Laboratories(米国)、WuXi AppTec(中国)、Eurofins Scientific(ルクセンブルク)、SGS(スイス)、Intertek Group(英国)、Nelson Laboratories, LLC(a Sotera Health company、米国)、Microbac Laboratories, Inc.(米国)、Almac Group(英国)、North American Science Associates, Inc.(英国)となっています。(米国)、Toxikon(米国)、Pacific Biolabs(米国)、MSL Solution Providers(英国)、Intertek Group PLC(英国)、Accugen Laboratories, Inc.(米国)、 Consumer Product Testing Company(米国)、Lucideon(英国)、 BioScience Laboratories, Inc(米国)、ALS Limited(オーストラリア)、 Microchem Laboratory(米国)、 Oxford Biosciences Ltd. (米国), Inc.(英国)、Abbott Analytical(オーストラリア)、Helvic Laboratories(a Tentamus Company、英国)、Honeyman Group Limited(英国)、Danish Technological Institute(DTI、デンマーク)、BluTest Laboratories Limited(英国)などがあります。 調査対象 本レポートでは、地域(アジア太平洋、欧州、北米、RoW)、サービスタイプ(殺菌効力試験、抗菌・防腐効力試験)、用途(医薬品製造用途、化粧品・パーソナルケア製品用途、消費財用途、医療機器用途)に基づき効力試験市場をセグメントしています。 また、効能試験市場における市場促進要因、課題、機会に関する包括的なレビューも提供しています レポート購入の主なメリット 本レポートは、市場全体とサブセグメントに関する収益数の最も近い近似値に関する情報を提供し、この市場のリーダー/新規参入者を支援します。本レポートは、利害関係者が競争環境を理解し、より良いビジネスの位置づけと適切な市場参入戦略を計画するためのより多くの洞察を得るのに役立ちます。また、本レポートは、利害関係者が効能試験市場の鼓動を理解するのに役立ち、主要な市場促進要因、課題、機会に関する情報を提供します。 本レポートは、以下のポイントに関する洞察を提供します。 - 市場の浸透度。効能試験市場におけるトッププレイヤーの製品ポートフォリオに関する包括的な情報。本レポートでは、サービスタイプ、アプリケーション、地域に基づいて市場を分析しています。 - サービスの開発/革新。有効性試験市場における今後の技術、研究開発活動、サービス/製品の発売に関する詳細な洞察。 - 市場開発。有利な新興市場に関する包括的な情報。本レポートでは、地域ごとに様々なタイプの効能試験ソリューションの市場を分析しています。 - 市場の多様化。有効性試験市場における製品/サービス、未開拓地域、最近の開発、投資に関する詳細な情報を提供します。 - 競争力の評価。有効性試験市場における主要企業の市場シェア、戦略、製品、流通網、製造能力に関する詳細な評価を行います。 目次1 INTRODUCTION 241.1 STUDY OBJECTIVES 24 1.2 MARKET DEFINITION 24 1.2.1 INCLUSIONS AND EXCLUSIONS 25 1.3 MARKET SCOPE 25 1.3.1 MARKETS COVERED 25 1.3.2 YEARS CONSIDERED 26 1.4 CURRENCY 26 1.5 LIMITATIONS 26 1.6 STAKEHOLDERS 27 1.7 SUMMARY OF CHANGES 27 2 RESEARCH METHODOLOGY 28 2.1 RESEARCH APPROACH 28 2.1.1 SECONDARY DATA 28 2.1.2 PRIMARY DATA 28 2.1.2.1 Breakdown of primary sources 29 FIGURE 1 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 29 2.1.2.2 Key industry insights 30 2.2 MARKET SIZE ESTIMATION 30 FIGURE 2 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 30 FIGURE 3 EFFICACY TESTING MARKET: FINAL CAGR PROJECTIONS 31 FIGURE 4 EFFICACY TESTING MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 32 FIGURE 5 EFFICACY TESTING MARKET: SEGMENTAL ASSESSMENT 33 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 34 FIGURE 6 DATA TRIANGULATION METHODOLOGY 34 2.4 MARKET RANKING ANALYSIS 35 2.5 RESEARCH ASSUMPTIONS 35 3 EXECUTIVE SUMMARY 36 FIGURE 7 EFFICACY TESTING MARKET, BY SERVICE TYPE, 2022 VS. 2027 (USD MILLION) 36 FIGURE 8 EFFICACY TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 37 FIGURE 9 REGIONAL SNAPSHOT OF EFFICACY TESTING MARKET 37 4 PREMIUM INSIGHTS 39 4.1 EFFICACY TESTING MARKET OVERVIEW 39 FIGURE 10 GROWING PREFERENCE FOR OUTSOURCING EFFICACY TESTING TO DRIVE MARKET GROWTH 39 4.2 ASIA PACIFIC: EFFICACY TESTING MARKET, BY APPLICATION AND COUNTRY (2021) 40 FIGURE 11 PHARMACEUTICAL MANUFACTURING APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021 40 4.3 GEOGRAPHICAL SNAPSHOT OF EFFICACY TESTING MARKET 41 FIGURE 12 CHINA TO WITNESS HIGHEST GROWTH RATE FROM 2022 TO 2027 41 4.4 EFFICACY TESTING MARKET, BY REGION 41 FIGURE 13 NORTH AMERICA TO DOMINATE MARKET IN 2027 41 4.5 EFFICACY TESTING MARKET: DEVELOPED VS. DEVELOPING MARKETS 42 FIGURE 14 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 42 5 MARKET OVERVIEW 43 5.1 INTRODUCTION 43 5.2 MARKET DYNAMICS 43 FIGURE 15 EFFICACY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43 5.2.1 DRIVERS 44 5.2.1.1 Increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability 44 5.2.1.1.1 Growing focus on contamination control 44 5.2.1.1.2 Increasing concerns over product stability 44 5.2.1.2 Growing preference for outsourcing efficacy testing 44 5.2.1.3 Rising adoption of quality by design approach 45 5.2.1.4 Stringent regulations for use of surface disinfectants 45 5.2.1.5 Growing awareness of sanitization and hygiene due to spread of COVID-19 46 5.2.2 RESTRAINTS 46 5.2.2.1 Adverse effects of chemical disinfectants 46 5.2.3 OPPORTUNITIES 47 5.2.3.1 Emerging countries in Asia Pacific 47 5.2.4 CHALLENGES 47 5.2.4.1 Time-consuming process 47 5.3 REGULATORY ANALYSIS 47 5.3.1 DISINFECTANT EFFICACY TESTING 48 5.3.2 ANTIMICROBIAL EFFICACY TESTING 48 5.4 IMPACT OF COVID-19 ON EFFICACY TESTING SERVICES 49 5.5 PRICING ANALYSIS 49 TABLE 1 PRICE OF SURFACE DISINFECTANT PRODUCTS (2022) 49 5.6 PATENT ANALYSIS 51 5.7 TRADE ANALYSIS 51 5.7.1 TRADE ANALYSIS FOR DISINFECTANTS 51 TABLE 2 IMPORT DATA FOR DISINFECTANTS, BY COUNTRY, 2018–2022 (USD MILLION) 51 TABLE 3 EXPORT DATA FOR DISINFECTANTS, BY COUNTRY, 2018–2022 (USD MILLION) 52 5.8 VALUE CHAIN ANALYSIS 52 FIGURE 16 VALUE CHAIN ANALYSIS: EFFICACY TESTING MARKET 52 5.9 ECOSYSTEM ANALYSIS 53 FIGURE 17 SURFACE DISINFECTANTS MARKET: ECOSYSTEM ANALYSIS 53 TABLE 4 ROLE IN ECOSYSTEM 54 5.10 PORTER’S FIVE FORCES ANALYSIS 55 TABLE 5 EFFICACY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 55 5.10.1 THREAT OF NEW ENTRANTS 55 5.10.2 THREAT OF SUBSTITUTES 55 5.10.3 BARGAINING POWER OF BUYERS 55 5.10.4 BARGAINING POWER OF SUPPLIERS 55 5.10.5 DEGREE OF COMPETITION 56 5.11 TECHNOLOGY ANALYSIS 56 6 EFFICACY TESTING MARKET, BY SERVICE TYPE 57 6.1 INTRODUCTION 58 TABLE 6 EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 58 6.2 DISINFECTANT EFFICACY TESTING 58 TABLE 7 DISINFECTANT EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 58 TABLE 8 NORTH AMERICA: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59 TABLE 9 EUROPE: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59 TABLE 10 APAC: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59 TABLE 11 ROW: DISINFECTANT EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 60 TABLE 12 DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 60 6.2.1 SURFACE TEST METHOD 60 6.2.1.1 Surface test method segment to account for larger share of disinfectant efficacy testing market 60 TABLE 13 SURFACE TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 61 TABLE 14 NORTH AMERICA: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 61 TABLE 15 EUROPE: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 61 TABLE 16 APAC: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 62 6.2.2 SUSPENSION TEST METHOD 62 6.2.2.1 Suspension test method is typically performed by researchers during development stage of disinfectants 62 TABLE 17 SUSPENSION TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 62 TABLE 18 NORTH AMERICA: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63 TABLE 19 EUROPE: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63 TABLE 20 APAC: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63 6.3 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING 64 TABLE 21 EUROFINS SCIENTIFIC AET TEST PROTOCOL 64 TABLE 22 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 64 TABLE 23 NORTH AMERICA: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65 TABLE 24 EUROPE: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65 TABLE 25 APAC: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65 TABLE 26 ROW: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 66 TABLE 27 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 66 6.3.1 TRADITIONAL TEST METHOD 66 6.3.1.1 Traditional test method segment to dominate AET/PET market 66 TABLE 28 TRADITIONAL TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 67 6.3.2 RAPID TEST METHOD 67 6.3.2.1 Regulatory uncertainties restraining adoption of rapid microbial methods 67 TABLE 29 RAPID TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 67 7 EFFICACY TESTING MARKET, BY APPLICATION 68 7.1 INTRODUCTION 69 TABLE 30 EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 69 7.2 PHARMACEUTICAL MANUFACTURING APPLICATIONS 69 7.2.1 INCREASING FOCUS ON ENSURING QUALITY OF DRUGS TO DRIVE SEGMENT GROWTH 69 TABLE 31 EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 70 TABLE 32 NORTH AMERICA: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 70 TABLE 33 EUROPE: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 70 TABLE 34 APAC: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 71 7.3 COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS 71 7.3.1 EFFICACY TESTING IS AN ESSENTIAL PART OF STABILITY TESTING REGIMEN OF COSMETICS 71 TABLE 35 EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 71 TABLE 36 NORTH AMERICA: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 72 TABLE 37 EUROPE: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 72 TABLE 38 APAC: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 72 7.4 CONSUMER PRODUCT APPLICATIONS 73 7.4.1 GROWING FOCUS ON HEALTHY ENVIRONMENT IN HOMES AND INDUSTRIAL FACILITIES TO DRIVE SEGMENT GROWTH 73 TABLE 39 EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 73 TABLE 40 NORTH AMERICA: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 73 TABLE 41 EUROPE: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 74 TABLE 42 APAC: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 74 7.5 MEDICAL DEVICE APPLICATIONS 74 7.5.1 IMPOSITION OF STRINGENT GOVERNMENT REGULATIONS TO DRIVE SEGMENT GROWTH 74 TABLE 43 EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 75 TABLE 44 NORTH AMERICA: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 75 TABLE 45 EUROPE: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 76 TABLE 46 APAC: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 76 8 EFFICACY TESTING MARKET, BY REGION 77 8.1 INTRODUCTION 78 TABLE 47 EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 78 8.2 NORTH AMERICA 78 FIGURE 18 NORTH AMERICA: EFFICACY TESTING MARKET SNAPSHOT 79 TABLE 48 NORTH AMERICA: EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 79 TABLE 49 NORTH AMERICA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 80 TABLE 50 NORTH AMERICA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 80 TABLE 51 NORTH AMERICA: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 80 TABLE 52 NORTH AMERICA: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 81 8.2.1 US 81 8.2.1.1 US to dominate North American efficacy testing market during forecast period 81 TABLE 53 US: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 81 TABLE 54 US: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 82 TABLE 55 US: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 82 8.2.2 CANADA 82 8.2.2.1 Government initiatives to drive market growth in Canada 82 TABLE 56 CANADA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 83 TABLE 57 CANADA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 83 TABLE 58 CANADA: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 83 8.3 EUROPE 84 TABLE 59 EUROPE: EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84 TABLE 60 EUROPE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 84 TABLE 61 EUROPE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 85 TABLE 62 EUROPE: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 85 TABLE 63 EUROPE: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 85 8.3.1 GERMANY 86 8.3.1.1 Germany to account for largest share in European market 86 TABLE 64 GERMANY: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 86 TABLE 65 GERMANY: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 86 TABLE 66 GERMANY: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 86 8.3.2 FRANCE 87 8.3.2.1 High demand for cosmetics in France to drive market growth 87 TABLE 67 FRANCE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 87 TABLE 68 FRANCE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 87 TABLE 69 FRANCE: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 88 8.3.3 UK 88 8.3.3.1 Efficacy testing market in UK is primarily driven by enforcement of regulatory and industry standards 88 TABLE 70 UK: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 88 TABLE 71 UK: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 89 TABLE 72 UK: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 89 8.3.4 ITALY 89 8.3.4.1 Increasing pharmaceutical production in Italy to drive market growth 89 TABLE 73 ITALY: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 90 TABLE 74 ITALY: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 90 TABLE 75 ITALY: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 90 8.3.5 SPAIN 90 8.3.5.1 Rising R&D expenditure to boost market growth in Spain 90 TABLE 76 SPAIN: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 91 TABLE 77 SPAIN: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 91 TABLE 78 SPAIN: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 91 8.3.6 REST OF EUROPE 92 TABLE 79 ROE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 92 TABLE 80 ROE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 92 TABLE 81 ROE: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 92 8.4 ASIA PACIFIC 93 FIGURE 19 ASIA PACIFIC: EFFICACY TESTING MARKET SNAPSHOT 93 TABLE 82 APAC: EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94 TABLE 83 APAC: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 94 TABLE 84 APAC: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 94 TABLE 85 APAC: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 94 TABLE 86 APAC: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 95 8.4.1 CHINA 95 8.4.1.1 China to dominate Asia Pacific market 95 TABLE 87 CHINA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 95 TABLE 88 CHINA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 96 TABLE 89 CHINA: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 96 8.4.2 JAPAN 96 8.4.2.1 Rising R&D investments to drive market growth in Japan 96 TABLE 90 JAPAN: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 96 TABLE 91 JAPAN: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 97 TABLE 92 JAPAN: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 97 8.4.3 INDIA 97 8.4.3.1 Growing pharmaceutical industry in India to drive market growth 97 TABLE 93 INDIA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 98 TABLE 94 INDIA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 98 TABLE 95 INDIA: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98 8.4.4 REST OF ASIA PACIFIC 98 TABLE 96 ROAPAC: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 99 TABLE 97 ROAPAC: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 99 TABLE 98 ROAPAC: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 99 8.5 REST OF THE WORLD 100 TABLE 99 ROW: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 100 TABLE 100 ROW: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 100 TABLE 101 ROW: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 100 TABLE 102 ROW: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 101 TABLE 103 ROW: EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 101 8.5.1 LATIN AMERICA 101 8.5.1.1 Increasing pharmaceutical R&D expenditure to drive market growth in Latin America 101 TABLE 104 LATAM: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 101 TABLE 105 LATAM: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 102 8.5.2 MIDDLE EAST AND AFRICA 102 8.5.2.1 UAE has emerged as key market in MEA region 102 TABLE 106 MEA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 102 TABLE 107 MEA: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 103 9 COMPETITIVE LANDSCAPE 104 9.1 OVERVIEW 104 9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 105 FIGURE 20 KEY DEVELOPMENTS IN EFFICACY TESTING MARKET, 2019–2022 105 9.3 MARKET SHARE ANALYSIS 106 FIGURE 21 EFFICACY TESTING MARKET SHARE, BY KEY PLAYER, 2021 106 TABLE 108 EFFICACY TESTING MARKET: DEGREE OF COMPETITION 106 9.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 107 9.5 COMPANY EVALUATION QUADRANT 108 9.5.1 STARS 108 9.5.2 EMERGING LEADERS 108 9.5.3 PERVASIVE PLAYERS 108 9.5.4 PARTICIPANTS 108 9.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 110 9.6.1 PROGRESSIVE COMPANIES 110 9.6.2 STARTING BLOCKS 110 9.6.3 RESPONSIVE COMPANIES 110 9.6.4 DYNAMIC COMPANIES 110 9.7 FOOTPRINT ANALYSIS OF COMPANIES 112 9.7.1 SERVICE FOOTPRINT OF COMPANIES 112 TABLE 109 SERVICE FOOTPRINT OF COMPANIES: EFFICACY TESTING MARKET (2021) 112 9.7.2 REGIONAL FOOTPRINT OF COMPANIES 113 TABLE 110 REGIONAL FOOTPRINT OF COMPANIES: EFFICACY TESTING MARKET (2021) 113 9.8 COMPETITIVE SCENARIO 114 TABLE 111 PRODUCT LAUNCHES 114 TABLE 112 DEALS 114 TABLE 113 OTHER DEVELOPMENTS 115 10 COMPANY PROFILES 116 10.1 EFFICACY TESTING SERVICE PROVIDERS 116 (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 10.1.1 EUROFINS SCIENTIFIC 116 TABLE 114 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 116 FIGURE 25 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021) 117 10.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 119 TABLE 115 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW 119 FIGURE 26 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021) 120 10.1.3 WUXI APPTEC 122 TABLE 116 WUXI APPTEC: BUSINESS OVERVIEW 122 FIGURE 27 WUXI APPTEC: COMPANY SNAPSHOT (2021) 123 10.1.4 SGS SA 125 TABLE 117 SGS SA: BUSINESS OVERVIEW 125 10.1.5 INTERTEK GROUP PLC 127 TABLE 118 INTERTEK GROUP PLC: BUSINESS OVERVIEW 127 FIGURE 28 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2021) 128 10.1.6 MICROCHEM LABORATORY 130 TABLE 119 MICROCHEM LABORATORY: BUSINESS OVERVIEW 130 10.1.7 ACCUGEN LABORATORIES, INC. 131 TABLE 120 ACCUGEN LABORATORIES, INC.: BUSINESS OVERVIEW 131 10.1.8 PACIFIC BIOLABS 133 TABLE 121 PACIFIC BIOLABS: BUSINESS OVERVIEW 133 10.1.9 NORTH AMERICAN SCIENCE ASSOCIATES 134 TABLE 122 NORTH AMERICAN SCIENCE ASSOCIATES: BUSINESS OVERVIEW 134 10.1.10 TOXIKON 135 TABLE 123 TOXIKON: BUSINESS OVERVIEW 135 10.1.11 BIOSCIENCE LABORATORIES, INC. 136 TABLE 124 BIOSCIENCE LABORATORIES, INC.: BUSINESS OVERVIEW 136 10.1.12 CONSUMER PRODUCT TESTING COMPANY (CPTC) 137 TABLE 125 CONSUMER PRODUCT TESTING COMPANY (CPTC): BUSINESS OVERVIEW 137 10.1.13 ALMAC GROUP 138 TABLE 126 ALMAC GROUP: BUSINESS OVERVIEW 138 10.1.14 MSL SOLUTION PROVIDERS 139 TABLE 127 MSL SOLUTION PROVIDERS: BUSINESS OVERVIEW 139 10.1.15 NELSON LABORATORIES, LLC (A SOTERA HEALTH COMPANY) 140 TABLE 128 NELSON LABORATORIES, LLC: BUSINESS OVERVIEW 140 10.1.16 ALS LIMITED 141 TABLE 129 ALS LIMITED: BUSINESS OVERVIEW 141 10.1.17 ABBOTT ANALYTICAL 142 TABLE 130 ABBOTT ANALYTICAL: BUSINESS OVERVIEW 142 10.1.18 BLUTEST LABORATORIES LIMITED 143 TABLE 131 BLUTEST LABORATORIES LIMITED: BUSINESS OVERVIEW 143 10.1.19 LUCIDEON 144 TABLE 132 LUCIDEON: BUSINESS OVERVIEW 144 10.1.20 HELVIC LABORATORIES (A TENTAMUS COMPANY) 145 TABLE 133 HELVIC LABORATORIES: BUSINESS OVERVIEW 145 10.2 MANUFACTURERS OF DISINFECTANTS 146 10.2.1 PROCTER & GAMBLE 146 TABLE 134 PROCTER & GAMBLE: BUSINESS OVERVIEW 146 FIGURE 29 PROCTER & GAMBLE: COMPANY SNAPSHOT (2021) 147 10.2.2 THE CLOROX COMPANY 149 TABLE 135 THE CLOROX COMPANY: BUSINESS OVERVIEW 149 FIGURE 30 THE CLOROX COMPANY: COMPANY SNAPSHOT (2021) 149 10.2.3 3M 152 TABLE 136 3M: BUSINESS OVERVIEW 152 FIGURE 31 3M: COMPANY SNAPSHOT (2021) 153 10.2.4 RECKITT BENCKISER GROUP PLC 155 TABLE 137 RECKITT BENCKISER GROUP PLC: BUSINESS OVERVIEW 155 FIGURE 32 RECKITT BENCKISER GROUP PLC: COMPANY SNAPSHOT (2021) 156 10.2.5 ECOLAB 158 TABLE 138 ECOLAB: BUSINESS OVERVIEW 158 FIGURE 33 ECOLAB: COMPANY SNAPSHOT (2021) 159 10.2.6 STERIS 162 TABLE 139 STERIS: BUSINESS OVERVIEW 162 FIGURE 34 STERIS: COMPANY SNAPSHOT (2021) 163 10.2.7 CANTEL MEDICAL 165 TABLE 140 CANTEL MEDICAL: BUSINESS OVERVIEW 165 FIGURE 35 CANTEL MEDICAL: COMPANY SNAPSHOT (2021) 166 10.2.8 DIVERSEY HOLDINGS LTD. 168 TABLE 141 DIVERSEY HOLDINGS LTD.: BUSINESS OVERVIEW 168 FIGURE 36 DIVERSEY HOLDINGS LTD.: COMPANY SNAPSHOT (2021) 168 10.2.9 CARROLLCLEAN 171 TABLE 142 CARROLLCLEAN: BUSINESS OVERVIEW 171 10.2.10 PAUL HARTMANN AG 173 TABLE 143 PAUL HARTMANN AG: BUSINESS OVERVIEW 173 *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 11 APPENDIX 175 11.1 DISCUSSION GUIDE 175 11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 177 11.3 AVAILABLE CUSTOMIZATIONS 179 11.4 RELATED REPORTS 180 11.5 AUTHOR DETAILS 181
SummaryThe global efficacy testing market is projected to reach USD 423 million by 2027 from USD 315 million in 2022, at a CAGR of 6.1% during the forecast period. The growth of this market is mainly driven by the increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability; growing preference for outsourcing efficacy testing; and the rising adoption of the QbD approach. The high growth potential in emerging markets will provide growth opportunities for players operating in the efficacy testing market. Table of Contents1 INTRODUCTION 241.1 STUDY OBJECTIVES 24 1.2 MARKET DEFINITION 24 1.2.1 INCLUSIONS AND EXCLUSIONS 25 1.3 MARKET SCOPE 25 1.3.1 MARKETS COVERED 25 1.3.2 YEARS CONSIDERED 26 1.4 CURRENCY 26 1.5 LIMITATIONS 26 1.6 STAKEHOLDERS 27 1.7 SUMMARY OF CHANGES 27 2 RESEARCH METHODOLOGY 28 2.1 RESEARCH APPROACH 28 2.1.1 SECONDARY DATA 28 2.1.2 PRIMARY DATA 28 2.1.2.1 Breakdown of primary sources 29 FIGURE 1 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 29 2.1.2.2 Key industry insights 30 2.2 MARKET SIZE ESTIMATION 30 FIGURE 2 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS 30 FIGURE 3 EFFICACY TESTING MARKET: FINAL CAGR PROJECTIONS 31 FIGURE 4 EFFICACY TESTING MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 32 FIGURE 5 EFFICACY TESTING MARKET: SEGMENTAL ASSESSMENT 33 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 34 FIGURE 6 DATA TRIANGULATION METHODOLOGY 34 2.4 MARKET RANKING ANALYSIS 35 2.5 RESEARCH ASSUMPTIONS 35 3 EXECUTIVE SUMMARY 36 FIGURE 7 EFFICACY TESTING MARKET, BY SERVICE TYPE, 2022 VS. 2027 (USD MILLION) 36 FIGURE 8 EFFICACY TESTING MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 37 FIGURE 9 REGIONAL SNAPSHOT OF EFFICACY TESTING MARKET 37 4 PREMIUM INSIGHTS 39 4.1 EFFICACY TESTING MARKET OVERVIEW 39 FIGURE 10 GROWING PREFERENCE FOR OUTSOURCING EFFICACY TESTING TO DRIVE MARKET GROWTH 39 4.2 ASIA PACIFIC: EFFICACY TESTING MARKET, BY APPLICATION AND COUNTRY (2021) 40 FIGURE 11 PHARMACEUTICAL MANUFACTURING APPLICATIONS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021 40 4.3 GEOGRAPHICAL SNAPSHOT OF EFFICACY TESTING MARKET 41 FIGURE 12 CHINA TO WITNESS HIGHEST GROWTH RATE FROM 2022 TO 2027 41 4.4 EFFICACY TESTING MARKET, BY REGION 41 FIGURE 13 NORTH AMERICA TO DOMINATE MARKET IN 2027 41 4.5 EFFICACY TESTING MARKET: DEVELOPED VS. DEVELOPING MARKETS 42 FIGURE 14 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 42 5 MARKET OVERVIEW 43 5.1 INTRODUCTION 43 5.2 MARKET DYNAMICS 43 FIGURE 15 EFFICACY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43 5.2.1 DRIVERS 44 5.2.1.1 Increasing use of surface disinfectants and preservatives in pharma, biopharma, and cosmetics industries for contamination control and product stability 44 5.2.1.1.1 Growing focus on contamination control 44 5.2.1.1.2 Increasing concerns over product stability 44 5.2.1.2 Growing preference for outsourcing efficacy testing 44 5.2.1.3 Rising adoption of quality by design approach 45 5.2.1.4 Stringent regulations for use of surface disinfectants 45 5.2.1.5 Growing awareness of sanitization and hygiene due to spread of COVID-19 46 5.2.2 RESTRAINTS 46 5.2.2.1 Adverse effects of chemical disinfectants 46 5.2.3 OPPORTUNITIES 47 5.2.3.1 Emerging countries in Asia Pacific 47 5.2.4 CHALLENGES 47 5.2.4.1 Time-consuming process 47 5.3 REGULATORY ANALYSIS 47 5.3.1 DISINFECTANT EFFICACY TESTING 48 5.3.2 ANTIMICROBIAL EFFICACY TESTING 48 5.4 IMPACT OF COVID-19 ON EFFICACY TESTING SERVICES 49 5.5 PRICING ANALYSIS 49 TABLE 1 PRICE OF SURFACE DISINFECTANT PRODUCTS (2022) 49 5.6 PATENT ANALYSIS 51 5.7 TRADE ANALYSIS 51 5.7.1 TRADE ANALYSIS FOR DISINFECTANTS 51 TABLE 2 IMPORT DATA FOR DISINFECTANTS, BY COUNTRY, 2018–2022 (USD MILLION) 51 TABLE 3 EXPORT DATA FOR DISINFECTANTS, BY COUNTRY, 2018–2022 (USD MILLION) 52 5.8 VALUE CHAIN ANALYSIS 52 FIGURE 16 VALUE CHAIN ANALYSIS: EFFICACY TESTING MARKET 52 5.9 ECOSYSTEM ANALYSIS 53 FIGURE 17 SURFACE DISINFECTANTS MARKET: ECOSYSTEM ANALYSIS 53 TABLE 4 ROLE IN ECOSYSTEM 54 5.10 PORTER’S FIVE FORCES ANALYSIS 55 TABLE 5 EFFICACY TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 55 5.10.1 THREAT OF NEW ENTRANTS 55 5.10.2 THREAT OF SUBSTITUTES 55 5.10.3 BARGAINING POWER OF BUYERS 55 5.10.4 BARGAINING POWER OF SUPPLIERS 55 5.10.5 DEGREE OF COMPETITION 56 5.11 TECHNOLOGY ANALYSIS 56 6 EFFICACY TESTING MARKET, BY SERVICE TYPE 57 6.1 INTRODUCTION 58 TABLE 6 EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 58 6.2 DISINFECTANT EFFICACY TESTING 58 TABLE 7 DISINFECTANT EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 58 TABLE 8 NORTH AMERICA: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59 TABLE 9 EUROPE: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59 TABLE 10 APAC: DISINFECTANT EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 59 TABLE 11 ROW: DISINFECTANT EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 60 TABLE 12 DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 60 6.2.1 SURFACE TEST METHOD 60 6.2.1.1 Surface test method segment to account for larger share of disinfectant efficacy testing market 60 TABLE 13 SURFACE TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 61 TABLE 14 NORTH AMERICA: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 61 TABLE 15 EUROPE: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 61 TABLE 16 APAC: SURFACE TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 62 6.2.2 SUSPENSION TEST METHOD 62 6.2.2.1 Suspension test method is typically performed by researchers during development stage of disinfectants 62 TABLE 17 SUSPENSION TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 62 TABLE 18 NORTH AMERICA: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63 TABLE 19 EUROPE: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63 TABLE 20 APAC: SUSPENSION TEST METHOD MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 63 6.3 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING 64 TABLE 21 EUROFINS SCIENTIFIC AET TEST PROTOCOL 64 TABLE 22 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 64 TABLE 23 NORTH AMERICA: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65 TABLE 24 EUROPE: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65 TABLE 25 APAC: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65 TABLE 26 ROW: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 66 TABLE 27 ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 66 6.3.1 TRADITIONAL TEST METHOD 66 6.3.1.1 Traditional test method segment to dominate AET/PET market 66 TABLE 28 TRADITIONAL TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 67 6.3.2 RAPID TEST METHOD 67 6.3.2.1 Regulatory uncertainties restraining adoption of rapid microbial methods 67 TABLE 29 RAPID TEST METHOD MARKET, BY REGION, 2020–2027 (USD MILLION) 67 7 EFFICACY TESTING MARKET, BY APPLICATION 68 7.1 INTRODUCTION 69 TABLE 30 EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 69 7.2 PHARMACEUTICAL MANUFACTURING APPLICATIONS 69 7.2.1 INCREASING FOCUS ON ENSURING QUALITY OF DRUGS TO DRIVE SEGMENT GROWTH 69 TABLE 31 EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 70 TABLE 32 NORTH AMERICA: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 70 TABLE 33 EUROPE: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 70 TABLE 34 APAC: EFFICACY TESTING MARKET FOR PHARMACEUTICAL MANUFACTURING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 71 7.3 COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS 71 7.3.1 EFFICACY TESTING IS AN ESSENTIAL PART OF STABILITY TESTING REGIMEN OF COSMETICS 71 TABLE 35 EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 71 TABLE 36 NORTH AMERICA: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 72 TABLE 37 EUROPE: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 72 TABLE 38 APAC: EFFICACY TESTING MARKET FOR COSMETICS AND PERSONAL CARE PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 72 7.4 CONSUMER PRODUCT APPLICATIONS 73 7.4.1 GROWING FOCUS ON HEALTHY ENVIRONMENT IN HOMES AND INDUSTRIAL FACILITIES TO DRIVE SEGMENT GROWTH 73 TABLE 39 EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 73 TABLE 40 NORTH AMERICA: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 73 TABLE 41 EUROPE: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 74 TABLE 42 APAC: EFFICACY TESTING MARKET FOR CONSUMER PRODUCT APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 74 7.5 MEDICAL DEVICE APPLICATIONS 74 7.5.1 IMPOSITION OF STRINGENT GOVERNMENT REGULATIONS TO DRIVE SEGMENT GROWTH 74 TABLE 43 EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 75 TABLE 44 NORTH AMERICA: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 75 TABLE 45 EUROPE: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 76 TABLE 46 APAC: EFFICACY TESTING MARKET FOR MEDICAL DEVICE APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 76 8 EFFICACY TESTING MARKET, BY REGION 77 8.1 INTRODUCTION 78 TABLE 47 EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 78 8.2 NORTH AMERICA 78 FIGURE 18 NORTH AMERICA: EFFICACY TESTING MARKET SNAPSHOT 79 TABLE 48 NORTH AMERICA: EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 79 TABLE 49 NORTH AMERICA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 80 TABLE 50 NORTH AMERICA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 80 TABLE 51 NORTH AMERICA: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 80 TABLE 52 NORTH AMERICA: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 81 8.2.1 US 81 8.2.1.1 US to dominate North American efficacy testing market during forecast period 81 TABLE 53 US: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 81 TABLE 54 US: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 82 TABLE 55 US: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 82 8.2.2 CANADA 82 8.2.2.1 Government initiatives to drive market growth in Canada 82 TABLE 56 CANADA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 83 TABLE 57 CANADA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 83 TABLE 58 CANADA: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 83 8.3 EUROPE 84 TABLE 59 EUROPE: EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 84 TABLE 60 EUROPE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 84 TABLE 61 EUROPE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 85 TABLE 62 EUROPE: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 85 TABLE 63 EUROPE: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 85 8.3.1 GERMANY 86 8.3.1.1 Germany to account for largest share in European market 86 TABLE 64 GERMANY: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 86 TABLE 65 GERMANY: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 86 TABLE 66 GERMANY: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 86 8.3.2 FRANCE 87 8.3.2.1 High demand for cosmetics in France to drive market growth 87 TABLE 67 FRANCE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 87 TABLE 68 FRANCE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 87 TABLE 69 FRANCE: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 88 8.3.3 UK 88 8.3.3.1 Efficacy testing market in UK is primarily driven by enforcement of regulatory and industry standards 88 TABLE 70 UK: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 88 TABLE 71 UK: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 89 TABLE 72 UK: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 89 8.3.4 ITALY 89 8.3.4.1 Increasing pharmaceutical production in Italy to drive market growth 89 TABLE 73 ITALY: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 90 TABLE 74 ITALY: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 90 TABLE 75 ITALY: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 90 8.3.5 SPAIN 90 8.3.5.1 Rising R&D expenditure to boost market growth in Spain 90 TABLE 76 SPAIN: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 91 TABLE 77 SPAIN: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 91 TABLE 78 SPAIN: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 91 8.3.6 REST OF EUROPE 92 TABLE 79 ROE: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 92 TABLE 80 ROE: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 92 TABLE 81 ROE: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 92 8.4 ASIA PACIFIC 93 FIGURE 19 ASIA PACIFIC: EFFICACY TESTING MARKET SNAPSHOT 93 TABLE 82 APAC: EFFICACY TESTING MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94 TABLE 83 APAC: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 94 TABLE 84 APAC: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 94 TABLE 85 APAC: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 94 TABLE 86 APAC: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 95 8.4.1 CHINA 95 8.4.1.1 China to dominate Asia Pacific market 95 TABLE 87 CHINA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 95 TABLE 88 CHINA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 96 TABLE 89 CHINA: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 96 8.4.2 JAPAN 96 8.4.2.1 Rising R&D investments to drive market growth in Japan 96 TABLE 90 JAPAN: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 96 TABLE 91 JAPAN: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 97 TABLE 92 JAPAN: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 97 8.4.3 INDIA 97 8.4.3.1 Growing pharmaceutical industry in India to drive market growth 97 TABLE 93 INDIA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 98 TABLE 94 INDIA: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 98 TABLE 95 INDIA: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 98 8.4.4 REST OF ASIA PACIFIC 98 TABLE 96 ROAPAC: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 99 TABLE 97 ROAPAC: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 99 TABLE 98 ROAPAC: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 99 8.5 REST OF THE WORLD 100 TABLE 99 ROW: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 100 TABLE 100 ROW: DISINFECTANT EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 100 TABLE 101 ROW: ANTIMICROBIAL/PRESERVATIVE EFFICACY TESTING MARKET, BY METHOD, 2020–2027 (USD MILLION) 100 TABLE 102 ROW: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 101 TABLE 103 ROW: EFFICACY TESTING MARKET, BY REGION, 2020–2027 (USD MILLION) 101 8.5.1 LATIN AMERICA 101 8.5.1.1 Increasing pharmaceutical R&D expenditure to drive market growth in Latin America 101 TABLE 104 LATAM: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 101 TABLE 105 LATAM: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 102 8.5.2 MIDDLE EAST AND AFRICA 102 8.5.2.1 UAE has emerged as key market in MEA region 102 TABLE 106 MEA: EFFICACY TESTING MARKET, BY SERVICE TYPE, 2020–2027 (USD MILLION) 102 TABLE 107 MEA: EFFICACY TESTING MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 103 9 COMPETITIVE LANDSCAPE 104 9.1 OVERVIEW 104 9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 105 FIGURE 20 KEY DEVELOPMENTS IN EFFICACY TESTING MARKET, 2019–2022 105 9.3 MARKET SHARE ANALYSIS 106 FIGURE 21 EFFICACY TESTING MARKET SHARE, BY KEY PLAYER, 2021 106 TABLE 108 EFFICACY TESTING MARKET: DEGREE OF COMPETITION 106 9.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 107 9.5 COMPANY EVALUATION QUADRANT 108 9.5.1 STARS 108 9.5.2 EMERGING LEADERS 108 9.5.3 PERVASIVE PLAYERS 108 9.5.4 PARTICIPANTS 108 9.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES 110 9.6.1 PROGRESSIVE COMPANIES 110 9.6.2 STARTING BLOCKS 110 9.6.3 RESPONSIVE COMPANIES 110 9.6.4 DYNAMIC COMPANIES 110 9.7 FOOTPRINT ANALYSIS OF COMPANIES 112 9.7.1 SERVICE FOOTPRINT OF COMPANIES 112 TABLE 109 SERVICE FOOTPRINT OF COMPANIES: EFFICACY TESTING MARKET (2021) 112 9.7.2 REGIONAL FOOTPRINT OF COMPANIES 113 TABLE 110 REGIONAL FOOTPRINT OF COMPANIES: EFFICACY TESTING MARKET (2021) 113 9.8 COMPETITIVE SCENARIO 114 TABLE 111 PRODUCT LAUNCHES 114 TABLE 112 DEALS 114 TABLE 113 OTHER DEVELOPMENTS 115 10 COMPANY PROFILES 116 10.1 EFFICACY TESTING SERVICE PROVIDERS 116 (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 10.1.1 EUROFINS SCIENTIFIC 116 TABLE 114 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 116 FIGURE 25 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2021) 117 10.1.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 119 TABLE 115 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW 119 FIGURE 26 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2021) 120 10.1.3 WUXI APPTEC 122 TABLE 116 WUXI APPTEC: BUSINESS OVERVIEW 122 FIGURE 27 WUXI APPTEC: COMPANY SNAPSHOT (2021) 123 10.1.4 SGS SA 125 TABLE 117 SGS SA: BUSINESS OVERVIEW 125 10.1.5 INTERTEK GROUP PLC 127 TABLE 118 INTERTEK GROUP PLC: BUSINESS OVERVIEW 127 FIGURE 28 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2021) 128 10.1.6 MICROCHEM LABORATORY 130 TABLE 119 MICROCHEM LABORATORY: BUSINESS OVERVIEW 130 10.1.7 ACCUGEN LABORATORIES, INC. 131 TABLE 120 ACCUGEN LABORATORIES, INC.: BUSINESS OVERVIEW 131 10.1.8 PACIFIC BIOLABS 133 TABLE 121 PACIFIC BIOLABS: BUSINESS OVERVIEW 133 10.1.9 NORTH AMERICAN SCIENCE ASSOCIATES 134 TABLE 122 NORTH AMERICAN SCIENCE ASSOCIATES: BUSINESS OVERVIEW 134 10.1.10 TOXIKON 135 TABLE 123 TOXIKON: BUSINESS OVERVIEW 135 10.1.11 BIOSCIENCE LABORATORIES, INC. 136 TABLE 124 BIOSCIENCE LABORATORIES, INC.: BUSINESS OVERVIEW 136 10.1.12 CONSUMER PRODUCT TESTING COMPANY (CPTC) 137 TABLE 125 CONSUMER PRODUCT TESTING COMPANY (CPTC): BUSINESS OVERVIEW 137 10.1.13 ALMAC GROUP 138 TABLE 126 ALMAC GROUP: BUSINESS OVERVIEW 138 10.1.14 MSL SOLUTION PROVIDERS 139 TABLE 127 MSL SOLUTION PROVIDERS: BUSINESS OVERVIEW 139 10.1.15 NELSON LABORATORIES, LLC (A SOTERA HEALTH COMPANY) 140 TABLE 128 NELSON LABORATORIES, LLC: BUSINESS OVERVIEW 140 10.1.16 ALS LIMITED 141 TABLE 129 ALS LIMITED: BUSINESS OVERVIEW 141 10.1.17 ABBOTT ANALYTICAL 142 TABLE 130 ABBOTT ANALYTICAL: BUSINESS OVERVIEW 142 10.1.18 BLUTEST LABORATORIES LIMITED 143 TABLE 131 BLUTEST LABORATORIES LIMITED: BUSINESS OVERVIEW 143 10.1.19 LUCIDEON 144 TABLE 132 LUCIDEON: BUSINESS OVERVIEW 144 10.1.20 HELVIC LABORATORIES (A TENTAMUS COMPANY) 145 TABLE 133 HELVIC LABORATORIES: BUSINESS OVERVIEW 145 10.2 MANUFACTURERS OF DISINFECTANTS 146 10.2.1 PROCTER & GAMBLE 146 TABLE 134 PROCTER & GAMBLE: BUSINESS OVERVIEW 146 FIGURE 29 PROCTER & GAMBLE: COMPANY SNAPSHOT (2021) 147 10.2.2 THE CLOROX COMPANY 149 TABLE 135 THE CLOROX COMPANY: BUSINESS OVERVIEW 149 FIGURE 30 THE CLOROX COMPANY: COMPANY SNAPSHOT (2021) 149 10.2.3 3M 152 TABLE 136 3M: BUSINESS OVERVIEW 152 FIGURE 31 3M: COMPANY SNAPSHOT (2021) 153 10.2.4 RECKITT BENCKISER GROUP PLC 155 TABLE 137 RECKITT BENCKISER GROUP PLC: BUSINESS OVERVIEW 155 FIGURE 32 RECKITT BENCKISER GROUP PLC: COMPANY SNAPSHOT (2021) 156 10.2.5 ECOLAB 158 TABLE 138 ECOLAB: BUSINESS OVERVIEW 158 FIGURE 33 ECOLAB: COMPANY SNAPSHOT (2021) 159 10.2.6 STERIS 162 TABLE 139 STERIS: BUSINESS OVERVIEW 162 FIGURE 34 STERIS: COMPANY SNAPSHOT (2021) 163 10.2.7 CANTEL MEDICAL 165 TABLE 140 CANTEL MEDICAL: BUSINESS OVERVIEW 165 FIGURE 35 CANTEL MEDICAL: COMPANY SNAPSHOT (2021) 166 10.2.8 DIVERSEY HOLDINGS LTD. 168 TABLE 141 DIVERSEY HOLDINGS LTD.: BUSINESS OVERVIEW 168 FIGURE 36 DIVERSEY HOLDINGS LTD.: COMPANY SNAPSHOT (2021) 168 10.2.9 CARROLLCLEAN 171 TABLE 142 CARROLLCLEAN: BUSINESS OVERVIEW 171 10.2.10 PAUL HARTMANN AG 173 TABLE 143 PAUL HARTMANN AG: BUSINESS OVERVIEW 173 *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 11 APPENDIX 175 11.1 DISCUSSION GUIDE 175 11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 177 11.3 AVAILABLE CUSTOMIZATIONS 179 11.4 RELATED REPORTS 180 11.5 AUTHOR DETAILS 181
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(その他(治療を主目的としない薬物))の最新刊レポートMarketsandMarkets 社の最新刊レポート
本レポートと同じKEY WORD(cosmetics)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/11/07 10:27 155.63 円 167.26 円 203.27 円 |